Page 77 of the full text is a grabber.  Could this be the mysterious Cpnⁱ factor that causes the immune mess that, in turn, causes too many in the medical/research communities to point the finger at autoimmunity?

"Next we elucidated the involvement of some surface components in the
cell-bacteria interaction. LPSⁱ is considered to be an important component
of C. pneumoniae in cellular activation (Costa et al., 2002; Da Costa et al.,
2004; Kalayoglu, 2002; Kalayoglu et al., 2000; Netea et al., 2002; Sasu et
al., 2001). In the present study, we found that the C. pneumoniae-induced
P-selectin expression was unaffected by heat treatment (70ºC, 30 min), but
prevented by the LPS-inhibitor polymyxin B, which supports a crucial role
for LPS in the interaction. Chlamydia LPS has a unique structure that
contains a pentaacyl-1,4´-diphosphoryl lipid A moiety instead of the
classical hexacyl-1,4´-diphosphoryl lipid A moiety and exposes a highly
immunogenic epitope on the polysaccharide core (Rund et al., 1999).
Interestingly, other bacteria with modified LPS, such as Porphyromonas
gingivalis, have been found to cause a more potent activation of platelets
than more classical gram-negative bacteria (Endo et al., 1997; Grabarek et
al., 1988). A recent study showed that LPS induces P-selectin-mediated
formation of platelet-leukocyte aggregation (Montrucchio et al., 2003),
which further supports a role for LPS in the stimulation of platelets in
inflammatory processes and atherosclerosis."

Joyce~caregiver-advocate in Dallas for Steve J (SPMSⁱ) / CAPⁱ since August 06, antivirals, heavy metal chelation, Metanx, Lunesta, Lauricidin, LDNⁱ, astaxanthin, oral IgG/lactoferrin/IGF-1 booster, gamma oryzanol.

CPnⁱ & Cardiac Disease - this a fascinating paper but lets remember that its about one area of CPn.  The implication is enormous for human health but it will take 10-20 years before the medical establishment is fully on board.  If proven, this could mean that producing a CPn vaccine is economically viable for big pharma.  However 20+ years in a likely timescale.  Forever a realist ... Mark.

Mark Walker - Oxford, England.

RRMSⁱ Nov 91, Dxⁱ 97. CFSⁱ Jan03. CAPⁱ (NACⁱ, Dox, Rox) with Copaxone Feb06. Monthly met pulses Jun06 to May 07. Pharma Consultant (worked til Jan03)